[
    [
        {
            "time": "2018-03-08",
            "original_text": "Shire plc (SHPG) Ex-Dividend Date Scheduled for March 08, 2018",
            "features": {
                "keywords": [
                    "Shire plc",
                    "Ex-Dividend",
                    "Scheduled"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-04-09",
            "original_text": "SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Johnson & Johnson (NYSE: JNJ) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit",
            "features": {
                "keywords": [
                    "SHAREHOLDER",
                    "ALERT",
                    "Johnson & Johnson",
                    "Class Action"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 2,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-03-01",
            "original_text": "U.S. judge says opioid settlement roadblocks may prompt trials",
            "features": {
                "keywords": [
                    "opioid",
                    "settlement",
                    "roadblocks",
                    "trials"
                ],
                "sentiment_score": -0.5,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 3,
                "Entity_Density": 5,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-03-01",
            "original_text": "Opioid Judge Allows Trial Prep as Settlement Talks Hit Snag",
            "features": {
                "keywords": [
                    "Opioid",
                    "Judge",
                    "Trial Prep",
                    "Settlement Talks"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 3,
                "Entity_Density": 5,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-03-01",
            "original_text": "Will Recent Trade War Talk Affect the Health Care Sector in March?",
            "features": {
                "keywords": [
                    "Trade War",
                    "Health Care Sector"
                ],
                "sentiment_score": -0.4,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-03-01",
            "original_text": "Why Gilead Sciences’ Harvoni Lost Market Share in 4Q17",
            "features": {
                "keywords": [
                    "Gilead Sciences",
                    "Harvoni",
                    "Market Share"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-03-01",
            "original_text": "Johnson & Johnson’s Pharmaceutical Segment in 4Q17",
            "features": {
                "keywords": [
                    "Johnson & Johnson",
                    "Pharmaceutical Segment"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        }
    ]
]